564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818646239701368832 |
|---|---|
| author | Ke Liu Christine Bonzon Seung Chu Rumana Rashid Umesh Muchhal John Desjarlais Matthew Bernett Nicole Rodriguez Nargess Hassanzadeh-Kiabi Connie Ardila |
| author_facet | Ke Liu Christine Bonzon Seung Chu Rumana Rashid Umesh Muchhal John Desjarlais Matthew Bernett Nicole Rodriguez Nargess Hassanzadeh-Kiabi Connie Ardila |
| author_sort | Ke Liu |
| collection | DOAJ |
| first_indexed | 2024-12-17T00:43:29Z |
| format | Article |
| id | doaj.art-15918c9564f44c03ac7e0a018ec5c174 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-17T00:43:29Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-15918c9564f44c03ac7e0a018ec5c1742022-12-21T22:09:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0564564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agentsKe Liu0Christine Bonzon1Seung Chu2Rumana Rashid3Umesh Muchhal4John Desjarlais5Matthew Bernett6Nicole Rodriguez7Nargess Hassanzadeh-Kiabi8Connie Ardila9Aff1 grid.417587.80000000122433366Office of Cellular, Tissue, and Gene Therapies (OCTGT)Center for Biologics Evaluation and Research (CBER) Rockville MD USA Aff390 Xencor, Inc. Monrovia CA USA Aff390 Xencor, Inc. Monrovia CA USA Aff390 Xencor, Inc. Monrovia CA USA Aff390 Xencor, Inc. Monrovia CA USA Aff390 Xencor, Inc. Monrovia CA USA Xencor, Inc., MONROVIA, CA, USAXencor, Inc., MONROVIA, CA, USAXencor, Inc., MONROVIA, CA, USAXencor, Inc., MONROVIA, CA, USA |
| spellingShingle | Ke Liu Christine Bonzon Seung Chu Rumana Rashid Umesh Muchhal John Desjarlais Matthew Bernett Nicole Rodriguez Nargess Hassanzadeh-Kiabi Connie Ardila 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents Journal for ImmunoTherapy of Cancer |
| title | 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents |
| title_full | 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents |
| title_fullStr | 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents |
| title_full_unstemmed | 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents |
| title_short | 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents |
| title_sort | 564 potency reduced and extended half life il12 heterodimeric fc fusions exhibit strong anti tumor activity with potentially improved therapeutic index compared to native il12 agents |
| work_keys_str_mv | AT keliu 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT christinebonzon 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT seungchu 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT rumanarashid 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT umeshmuchhal 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT johndesjarlais 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT matthewbernett 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT nicolerodriguez 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT nargesshassanzadehkiabi 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents AT connieardila 564potencyreducedandextendedhalflifeil12heterodimericfcfusionsexhibitstrongantitumoractivitywithpotentiallyimprovedtherapeuticindexcomparedtonativeil12agents |